Gold is 2025’s best performer. UBS sees more upside
MENLO PARK, Calif. - GRAIL, Inc. (NASDAQ:GRAL), a healthcare company focused on early cancer detection with a market capitalization of $1.24 billion, has announced a new partnership with athenahealth to integrate its Galleri® multi-cancer early detection (MCED) test into athenahealth’s electronic health record (EHR) platform. The company has shown remarkable market performance, delivering a 157% return over the past year. According to InvestingPro analysis, GRAIL maintains a strong financial health score despite being in its growth phase. The collaboration aims to streamline the process for clinicians to order the Galleri test, which is designed to detect multiple types of cancer from a single blood draw.
Through the integration with athenaCoordinator Core, part of athenahealth’s athenaOne service, over 160,000 clinicians on the athenahealth network will be able to order the Galleri test more efficiently during routine exams. With revenue growth of 34.9% in the last twelve months and a comfortable current ratio of 10.66, GRAIL appears well-positioned to support this expansion, though InvestingPro data indicates the company is currently burning through cash rapidly as it scales operations. This is expected to facilitate increased patient access to the test, which screens for cancers that are often deadly and may not have recommended screening tests, including pancreatic, esophageal, ovarian, and liver cancers.
Josh Ofman, MD, MSHS, president at GRAIL, emphasized the importance of early cancer detection and the role of the Galleri test in transforming cancer screening practices. The test works by identifying DNA fragments shed by cancer cells into the bloodstream, which can serve as a unique cancer "fingerprint."
The Galleri test, which is prescription only, is recommended for adults with an elevated risk for cancer, such as those aged 50 or older. It is intended to complement, not replace, other recommended cancer screenings. Test results are automatically integrated into the patient’s chart, reducing the administrative burden for healthcare providers.
While the Galleri test has shown high sensitivity in detecting certain cancers at various stages, it is not a comprehensive cancer screening tool and should be used in conjunction with other recommended screening methods. The test is not recommended for individuals who are pregnant, under 21 years old, or undergoing active cancer treatment.
This partnership reflects GRAIL’s ongoing efforts to reduce the global burden of cancer through early detection. The company, headquartered in Menlo Park, CA, utilizes next-generation sequencing and machine learning to detect cancer signals and predict their origin within the body.
The information for this article is based on a press release statement. For deeper insights into GRAIL’s financial health and growth prospects, including 10+ additional ProTips and comprehensive metrics, explore the detailed Pro Research Report available on InvestingPro.
In other recent news, Grail Inc. reported a notable increase in revenue for the fourth quarter of 2024, with a 26% year-over-year rise, reaching $38.3 million. Despite a net loss of $97.1 million, the company managed to reduce its quarterly loss by 48%, indicating improved financial health. For the full year, Grail’s revenue grew by 35% compared to 2023, totaling $125.6 million, primarily driven by a 45% increase in screening revenue from the sale of 137,000 Galleri tests. Canaccord Genuity recently initiated coverage of Grail with a Buy rating and a 12-month price target of $32.00, reflecting optimism about the company’s prospects. The firm acknowledged the potential challenges Grail faces, such as regulatory hurdles and market acceptance, but remains positive about its long-term growth potential. Additionally, Grail launched an enhanced version of its Galleri test, which is expected to improve efficiency and support testing at scale. The company maintained its 2025 guidance, with no revisions reported during the earnings call. Grail plans to complete its registrational studies and submit a modular PMA to the FDA by the first half of 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.